The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for both industry and patients.
We have set some goals not only as an industry but as a country: increase the production of high-value products not only in pharma but across all industries, create a suitable R&D environment through more funding and new public policies, and promote domestic production of biosimilar products
